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1. Introduction
Recent studies have reported adipose tissue as a crucial site for the generation of inflammatory
responses and mediators in metabolic syndrome. In addition to the intrinsic properties of
adipocytes in energy storage and metabolic homeostasis, adipose tissue serves as a key area
for the interaction of adipocytes with other factors of the immune system.
An important feature of inflammation is recruitment of immune cells such as neutrophils,
eosinophils, and macrophages. Macrophage infiltration of adipose tissue in obese conditions
has been studied in both mice and humans. It has been suggested that expanding adipocytes
or neighboring pre-adipocytes could start to produce chemotactic signals inducing to macro‐
phage recruitment, and this event is linked to systemic inflammation and insulin resistance.
In this chapter, we describe several chemotactic factors that have been implicated in the
recruitment of inflammatory monocytes and macrophages into adipose tissue.
2. Body
2.1. Adipose tissue inflammation
2.1.1. Adipose tissue as a site of inflammation: expansion of adipose tissue induces an inflammatory
response that contributes to metabolic disorders
2.1.1.1. Composition and function of adipose tissue
Adipose tissue is connective tissue composed primarily of adipocytes. The highest percentage
of cells within adipose tissue is adipocytes; other cell types present in adipose tissue are
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collectively termed the stromal vascular fraction (SVF), which includes pre-adipocytes,
adipose tissue macrophages, fibroblasts, and endothelial cells. Adipose tissue primarily plays
a role in the storage of energy in the form of lipids when nutrients are in excess or in the
regulation of homeostasis of non-shivering thermogenesis. Adipose tissue regulates whole
body energy homeostasis by responding rapidly and dynamically to changes in nutrient
deprivation and excess through regulation of adipocyte size and number [1, 2]. In this reaction,
free fatty acids (FFAs) are released from lipoproteins by lipoprotein lipase (LPL) and enter the
adipocyte, where they are reassembled into triglycerides by esterification onto glycerol.
Adipose tissue also provides feedback for hunger and diet to the brain under normal condi‐
tions through secretion of hormones [3].
2.1.1.2. Adipose tissue mediates obesity-induced inflammation
Obesity negatively affects the functioning of peripheral tissues, including adipose tissue,
skeletal muscle, the pancreas, liver, heart, joints, and central nervous system (CNS) [4]. The
fundamental characteristic of obesity is chronic imbalance between caloric intake and energy
expenditure, resulting in the storage of excess nutrients in white adipose tissue (WAT) [5].
WAT was traditionally considered a long-term energy storage organ, but it is now known that
it has a key role in the systemic regulation of metabolism. The metabolic function is largely
mediated by the ability of WAT to secrete numerous proteins [6, 7]. The cytokines secreted by
adipose tissue are called adipokines. In the obese state, the secretory status of adipose tissue
is modified by changes in the cellular composition, including diverse alterations in the number,
phenotype, and localization of immune, vascular, and structural cells [6]. Adipose tissue in
obese human patients and in animal models of obesity are infiltrated by a large number of
macrophages, and this recruitment is linked to systemic inflammation and insulin resistance
[8, 9]. The secretion of most adipokines is upregulated in the obese state, and these proteins
primarily include proinflammatory cytokines such as monocyte chemotactic protein-1
(MCP-1), TNF-α, and interleukin (IL)-6, which function to promote the development of a
chronic and systemic inflammatory state and contribute to metabolic dysfunction [6, 10, 11].
Therefore, adipose tissue-mediated inflammation is a considered to be a pathophysiological
condition (Figure 1).
Increased  levels  of  the  cytokine  TNF-α  in  adipose  tissue  of  obese  mice  were  the  first
discovered  link  between  inflammation  and  obesity  [12].  This  discovery  was  soon  fol‐
lowed by many studies describing changes in the levels of inflammatory molecules between
obese and lean states in animals as well as humans. It is now known that, in addition to
TNF-α, an array of inflammatory cytokines including IL-6, IL-1β, MCP-1, and others are
increased in obese tissues [13, 14].
2.1.2. Obesity-mediated macrophage recruitment into adipose tissue and metabolic disease
It is generally accepted that obesity causes adipocytes to secrete chemokines such as MCP-1
and leukotriene B4 (LTB4), which provide a chemotactic gradient that recruits monocytes into
adipose tissue, where they become adipose tissue macrophages (ATMs) (Figure 2). Once
proinflammatory ATMs migrate into adipose tissue, they also secrete their own cytokines,
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recruit additional macrophages, and ultimately set up an amplified inflammatory process [15].
Specifically, ATMs together with hypertrophic adipocytes, pre-adipocytes, and other immune
cells produce an array of chemokines, proinflammatory cytokines, and metabolites that induce
endothelial activation during obesity. This reaction causes endothelial cells to produce various
cellular adhesion molecules such as ICAMs, selectins, vascular cell adhesion molecules, and
PECAM-1. Through a rolling and adhesion step, monocytes slow down and finally bind to
endothelial adhesion proteins via selectin ligands and integrins. After a series of events
including actin-dependent spreading, polarization, the monocytes undergo integrin-depend‐
ent lateral migration on the luminal surface of the endothelium. Then, the monocytes migrate
across the endothelium, either through para-or transcellular routes [16]. After entering adipose
tissue, macrophages undergo differentiation towards M1-or M2-like macrophages (See Section
2.2) [17]. Differentiation processes can occur according to their initial circulating phenotype
and/or in response to local micro-environmental stimuli. However, repolarization of M1
macrophages into M2 macrophages and conversely, proliferation of macrophages within the
adipose tissue still remain unclear [17].
The recruitment of macrophages into adipose tissue is the initial and important event in
obesity-induced inflammation and metabolic disease [15]. Activation of tissue macrophages,
as the outcome, triggers the secretion of proinflammatory cytokines, which can induce insulin
resistance in various pathways. Genetic studies using knockout (KO) and transgenic techni‐
ques to disable macrophage-mediated inflammatory pathways also support this pathway [15].
Figure 1. Adipose tissue affects peripheral metabolic tissues and induces diverse metabolic syndrome complications
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Figure 2. Adipokines induce obesity-mediated immune cell recruitment into adipose tissue
2.2. Adipose tissue macrophages: types and functions in metabolic disease
2.2.1. Origin and function of ATM
Pre-adipocytes have been shown to convert to macrophages [18], but most ATMs migrate from
blood monocytes during obesity. Bone-marrow transplantation experiments using transgenic
mice with antigenically distinct forms of the CD45 protein, a leukocyte marker, showed that
85% of ATMs after 6 weeks of a high fat diet (HFD) were from donor cells, which indicates
that blood circulating monocytes migrated into adipose tissue while receiving the HFD [9].
Therefore, there are likely some signals that attract blood monocytes to adipose tissue (see
Section 2.3). Since ATMs are the primary source for proinflammatory cytokines in adipose
tissue, it was hypothesized that ATMs might be the critical player for systemic insulin
resistance. Several studies have supported this hypothesis in in vivo models. For example,
myeloid-specific IKKβ KO mice showed improved insulin sensitivity with the HFD [19], and
mice with JNK1 and 2 deficiencies in macrophages were obese but were still insulin sensitive
with fewer macrophages and lower proinflammatory cytokine expression in adipose tissues
[20]. These studies suggested that changes in macrophage activation might affect whole body
insulin sensitivity.
2.2.2. General aspects of macrophage activation
Macrophages are a heterogeneous cell population exhibiting a wide spectrum of phenotypes
due to cellular differentiation, wide spread tissue distribution, and responsiveness to many
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endogenous and exogenous stimuli. Macrophage activation has been defined across 2 separate
polarization states, M1 and M2 [21]. M1 macrophages are referred to as classical activated
macrophages where activation is dependent on products of specifically activated T helper 1
(TH1)-type lymphocytes and natural killer cells. Similar to interferon-gamma (IFN-γ) [22] and
IL-12, IL-18 is presented by antigen presenting cells (APCs). M1 macrophages secrete high
levels of proinflammatory cytokines (TNF-α, IL-6, IL-12) and generate reactive oxygen species
(ROS) through the actions of inducible nitric oxide synthase (NOS2). M2 macrophages are
activated by IL-4 and IL-13, cytokines produced generally in a TH-2-type response, which is
referred to as alternative activation. This type of activation is believed to be involved in allergic,
cellular, and humoral responses to parasitic and extracellular pathogens. M2 macrophages
secrete low levels of proinflammatory cytokines and high level of anti-inflammatory cytokines
[21]. Three different subsets of M2 macrophages have been identified, including M2a, M2b,
and M2c. IL-4 and IL-13 lead to M2a macrophages, immune complexes in combination with
IL-1b or lipopolysaccharide (LPS) drive the M2b subtype, whereas IL-10, TGF-β, or glucocor‐
ticoids induce M2c macrophages [23]. In alternative activation, IL-4 and IL-13 upregulate
expression of the mannose receptor and MHC class II molecules, which stimulate endocytosis
and antigen, while intracellular enzymes such as arginase are implicated in cell recruitment
and granuloma formation.
2.2.3. Activation of adipose tissue macrophages (ATMs)
Originally, ATMs were suggested to have roles in the production of proinflammatory cyto‐
kines [8, 9]; therefore, it seems plausible that most ATMs are M1 macrophages in obesity. In
initial pioneering studies regarding ATMs, ATM content was determined by F4/80 or CD11b
antibodies, which are common macrophage markers that cannot differentiate between M1 and
M2 macrophages. Subsequent studies have shown that ATMs are operationally defined across
M1 to M2 polarization states. Using flow cytometry, it was shown that ATM from lean mice
showed the M2 macrophage phenotype, but ATMs that accumulated following a HFD
exhibited the proinflammatory M1 phenotype. Based on these data, it was suggested that
ATMs underwent a phenotypic switch from the M2 polarization state to a more M1 polariza‐
tion state [24]. In line with ATM polarization, ATMs with M1-like activation were characterized
by F4/80+/CD11b+/CD11c+surface markers, whereas F4/80+/CD11b+/CD11c-cells were present
following M2-like activation [24, 25]. Since F4/80 and CD11c were primarily considered as
surface markers for macrophages and dendritic cells, respectively, these ATMs with triple
positive surface markers are unusual in that they have both macrophage and dendritic cell
features [25]. These data are supported by the fact that CD11c+cells have a deleterious effect
on insulin resistance; it was shown that selective depletion of CD11c+cells reversed insulin
resistance with a HFD [26]. A recent article showed the temporal dynamics of macrophage
activation where it was shown that M2 ATM polarization was enhanced in the early phase of
obesity (both in the ob/ob model and the diet-induced obesity (DIO) model), and M1 polariza‐
tion was subsequently gradually enhanced [27]. These data indicate that there are temporal
and spatio differences between M1 and M2 macrophages during obesity. While M2 macro‐
phages (resident macrophages) were localized to interstitial spaces between adipocytes in lean
mice, M1 ATMs surrounded dead adipocytes with DIO, thus forming crown-like structures
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(CLSs) [28]. However, the activation status of ATMs does not seem to be static. Whereas HFD-
induced insulin resistance followed by a normal chow diet could reverse body insulin
sensitivity, mice still contained a similar level of CD11c+ATMs in adipose tissue, but these
macrophages no longer exhibited inflammatory pathway markers [29]. Furthermore, a class
of macrophages that express a marker for both M1 and M2 (i.e., CD11c+, CD209a+) was
identified in obese adipose tissues. These macrophages were likely transformed from M2 to
M1 macrophages through lipid accumulation [27]. Therefore, there might be some mechanism
to regulate activation of ATMs in adipose tissue along with obesity development.
2.2.4. Regulation of ATM polarization
Classical activation of macrophages (M1) is induced by Toll-like receptor (TLR) ligands and
IFN-γ, while alternative activation of macrophages (M2) is induced by IL-4/IL-13 (M2a),
immune complexes (M2b), or anti-inflammatory cytokines IL-10 or TGF-β (M2c) to mediate
Th1/Th2 immune responses [30]. In the classical activation of macrophages, adipose tissue
secretes FFAs, which can activate TLR4 [31] by lipolysis and IFN-γ. On the other hand, it was
shown that adipocytes secrete Th2 cytokines such as IL-4 and IL-13, which is important for
alternative macrophage activation [32]. Adiponectin is also reported to induce M2 polarization,
which was shown using adiponectin KO mice and adenoviral delivery of adiponectin [33].
In terms of intracellular signaling in adipose tissue macrophages, transcription factors and
related machinery that regulate ATM polarization have been studied. Peroxisome proliferator–
activated receptor gamma (PPARγ) is one of most striking regulators because it is known as
a master regulator of adipogenesis. However, PPARγ was expressed at relatively high levels
in monocytes and macrophages [34], and it was reported that PPARγ activation reduced
proinflammatory cytokines in monocytes/macrophages [35, 36]. When PPARγ was knocked
out in macrophages, bone marrow-derived macrophages showed impaired alternative
macrophage activation, and these mice were obese, with an insulin resistant and glucose
intolerant phenotype following HFD feeding [37]. PPARδ, another PPAR family member, is
also important for ATM polarization. Myeloid-specific KO of PPARδ resulted in enhanced
adipose tissue inflammation and insulin resistance, which is consistent with the M1 polariza‐
tion phenotype [32]. PGC-1β, a co-activator of the PPAR family, is also clearly involved in
alternative macrophage activation by cooperating with STAT6, which is a critical signal
mediated by Th2 cytokines [38]. In addition, Krüppel-like factor 4 (KLF4), which belongs to
the zinc finger class of DNA-binding transcriptional regulators, was suggested to be a master
regulator of macrophage polarization during obesity. KLF4 expression was markedly reduced
in obese adipose tissue, and KLF4 deficiency exhibited an enhanced inflammatory response.
In particular, myeloid specific KO of KLF4 led to obesity, insulin resistance, and impaired
glucose tolerance [39]. Interferon regulatory factor 4 (IRF4) is also known to be involved in
ATM polarization. Macrophage-specific IRF4 KO mice exhibited significant insulin resistance
and adipose tissue inflammation with a HFD [40].
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2.3. Adipose tissue-derived chemotactic factors and macrophage recruitment in metabolic
diseases
Human studies and mouse models have both been used to identify the chemokines and
associated receptors that are elevated in obese adipose tissue [41] and those that contribute to
monocyte recruitment [17].
2.3.1. MCP-1 and CCR2
MCP-1 (CCL2) is produced mostly by macrophages and endothelial cells and is a potent
chemotactic factor for monocytes [42-44]. The level of MCP-1 in both WAT and plasma was
increased in obese mice [45], suggesting that MCP-1 might be an adipokine whose expression
is increased in obesity [46].
Binding of MCP-1 to its receptor CCR2 is considered crucial in obesity-induced insulin
resistance. Several groups have demonstrated that mice with targeted deletions in the genes
for Mcp-1 and its receptor Ccr2 have decreased ATM content, decreased inflammation in WAT,
and protection against obesity-induced insulin resistance [46, 47]. On the contrary to this, mice
overexpressing MCP-1 in adipose tissue had increased ATM and insulin resistance [46, 48].
Therefore, the MCP-1-CCR2 axis is important to promote ATM recruitment and insulin
resistance in mice. Recent studies; however, have shown conflicting results and indicate a
greater complexity than suggested by previous reports. In studies done by several groups,
results showed that loss of MCP-1 did not attenuate obesity-associated macrophage recruit‐
ment to WAT or improve metabolic function, suggesting that MCP-1 is not pivotal for obesity-
induced macrophage recruitment and systemic insulin resistance [49, 50]. Furthermore,
although Ccr2-/-mice fed a HFD had fewer macrophages in WAT compared with wild type
(WT) mice [47], CCR2 deficiency did not normalize ATM content and insulin resistance to the
levels in lean mice, indicating that ATM recruitment and insulin resistance are also regulated
by MCP-1-CCR2 independent signals. The intricacy and redundancy of chemokine signaling
may account for these conflicting results.
2.3.2. CCL3, CCL5, CCR1, and CCR5
Macrophage inflammatory protein-1 (MIP-1/CCL3) is a CC chemokine with upregulated
expression in obese WAT of humans and mice. CCL3 transcript and protein are remarkably
elevated in WAT of ob/ob, db/db, and DIO mice [8, 51]. In obese humans, the expression of CCL3
and its receptors CCR1 and CCR5 were increased in omental and subcutaneous WAT com‐
pared with normal weight individuals [41]. Moreover, expression of CCL3 and CCR1 in WAT
was positively correlated with fasting blood insulin levels in humans [41, 52, 53]. Although
many reports have shown a functional role of CCL3 in obesity, the consequences of this have
not been established [54].
Keophiphath et al. identified CCL5 as the most upregulated gene in human pre-adipocytes
provided with macrophage-secreted factors [55]. Although its role and its target receptors in
human WAT are unknown, this chemokine is involved in blood monocyte recruitment to
inflammatory sites by binding to the G-protein-coupled receptors CCR1, CCR3, and CCR5.
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CCL5 production in fibroblasts, platelets, and monocytes/macrophages is a known feature of
inflammatory disorders [56]. In atherosclerosis, CCL5, via CCR1 and CCR5, contributes to
transmigration of monocytes and T cells in atherogenic lesions [57].
Kitade et al. revealed that CCR5 plays a crucial role in the regulation of adipose tissue
inflammation in obesity and the development of insulin resistance [58]. Expression of CCR5
and its ligands is highly increased in WAT of both ob/ob and DIO mice. FACS analysis clearly
demonstrated that CCR5+macrophages accumulate in WAT of obese mice. The loss of CCR5
improved obesity-induced insulin resistance in mice. Both Ccr5-/-mice fed a HFD and mice
deficient in Ccr5 bone marrow-derived cells showed ameliorated insulin sensitivity and
protection from obesity-induced insulin resistance via reduction of ATM accumulation.
2.3.3. LTB4 and BLT-1
LTB4 is a kind of proinflammatory lipid mediator generated from arachidonic acid [59, 60].
LTB4 is rapidly produced by activated leukocytes, it promotes leukocyte chemotaxis, and
regulates proinflammatory cytokines [59, 61]. The biological actions of LTB4 are mediated by
an interaction with a G protein-coupled receptor termed BLT-1 [61]. Although the LTB4/BLT-1
axis plays a critical role in host defense during acute infection, chronic activation of this
pathway provides continuous inflammation, which is feature of inflammatory pathologies
such as atherosclerosis and arthritis [62-67]. Moreover, LTB4 levels increased in adipose tissue
of both mice and rats consuming a HFD [67-69]. Spite et al. reported that deficiency of BLT-1
protects against the progression of insulin resistance in DIO by regulating ATM accumulation
and inflammation in peripheral tissues [70].
2.3.4. Fractalkine (CX3CL1) and CX3CR1
CX3CL1, a chemokine that binds to a single known receptor (CX3CR1), is involved in the
recruitment and adhesion of both monocytes and T cells in atherosclerosis and rheumatologic
disorders [71]. CX3CR1 is a G-protein-coupled receptor expressed in many leukocyte subtypes
[72, 73] and promotes leukocyte activation and survival [74]. To develop macrophage-rich
atherosclerotic lesions, CX3CR1 is required for monocyte recruitment. [75, 76]. Digby et al.
suggested that adipocytes also expressed CX3CL1 and that CX3CR1 signaling in macrophages
was inhibited by PPARγ agonists [77]. Moreover, modulation of the CX3CL1/CX3CR1 system
can regulate chronic inflammatory diseases, including atherosclerosis, independent of CCL2/
CCR2 [78], which indicates that this also occur in adipose tissue inflammation and its related
complications. Recently, Shah et al. found that CX3CL1 is one of markedly upregulated genes
in human adipose tissue through in vivo inflammation by using a microarray of adipose tissue
mRNA during experimental endotoxemia [79, 80].
2.3.5. CXCL14
CXCL14 (originally designated as BRAK, BMAC, or Mip-2g) is expressed in WAT, brown
adipose  tissue  (BAT),  and  skeletal  muscle,  which  indicates  that  it  may  have  a  role  in
adipogenesis, myogenesis, and metabolic complications. CXCL14, as a chemoattractant, is
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required for activated tissue macrophages and dendritic cells [81-87]. Nara et al. generat‐
ed Cxcl14  deficient  mice  and described that  CXCL14 is  involved in  the  obesity-induced
infiltration  of  macrophages  into  WAT,  serum  adipokine  levels,  hepatic  steatosis,  and
attenuation of insulin signaling in skeletal muscle; thereby, contributing to systemic insulin
resistance in DIO mice [88].
2.3.6. Osteopontin
Osteopontin (OPN) is a secreted matrix glycoprotein and proinflammatory cytokine that has
previously been reported as a major element of cell-mediated immunity [89]. Many studies
have provided evidence that OPN is secreted by macrophages at sites of inflammation where
it mediates monocyte adhesion [90], migration [91], differentiation [92], and phagocytosis [93].
OPN play a role in the development of atherosclerosis. OPN induces chemotaxis of monocytes
and elevates cellular migration through a direct interaction with its receptors [94, 95]. No‐
miyama et al. demonstrated that OPN secretion is upregulated during obesity and greatly
expressed in ATMs of DIO mice, characterizing OPN as an adipokine. OPN deficiency
attenuated ATM accumulation, adipose tissue inflammation and improved whole body
insulin resistance [96].
2.3.7. Apoptosis inhibitor of macrophage (AIM/CD5L)
AIM [97] is incorporated into adipocytes via CD36-associated endocytosis, and it mediated
lipolysis by suppressing the activity of fatty acid synthase (FAS) [98]. AIM is a member of the
scavenger receptor cysteine-rich superfamily and was initially characterized as an apoptosis
inhibitor that supports the survival of macrophages against apoptosis-inducing stimuli [97].
AIM is a direct target for regulation by nuclear receptor liver X receptor/retinoid X receptor
(LXR/RXR) heterodimers [99, 100], and it is exclusively produced by tissue macrophages. As
a secreted molecule, AIM is found in both human and mouse blood [97, 100-103] and increases
in blood with the progression of obesity in DIO mice [98]. AIM-associated lipolysis is respon‐
sible for the obesity-induced recruitment of ATMs. Kurokawa et al. demonstrated the role of
AIM in the initiation of adipose tissue inflammation that links obesity and insulin resistance
[104]. Firstly, AIM-induced lipolysis is required for macrophage recruitment into obese
adipose tissues. Increased blood AIM levels induce dynamic lipolysis in obese adipose tissues,
augmenting local extracellular fatty acid concentrations to a level sufficient for the stimulation
of TLR4, which promotes chemokine production by adipocytes and macrophage infiltration.
Secondly, an increase in blood AIM is required as well as adipocyte hypertrophy for the
initiation of macrophage recruitment. In AIM deficient mice, although the level of AIM-
independent lipolysis escalated in line with adipocyte hypertrophy [98], it may not reach a
level sufficient for macrophage infiltration. Thirdly, crosstalk between adipocytes and
macrophages within adipose tissue establishes a vicious circle that accelerates inflammation;
saturated fatty acids brought about by lipolysis activated TLR4 to induce TNFα, which in turn
activated the TNFα receptor to produce inflammatory cytokines [105]. This response induces
a further progression of inflammation, lipolysis, and macrophage recruitment.
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2.3.8. Macrophage migration inhibitory factor (MIF)
MIF is a multifunctional proinflammatory cytokine which is responsible for inflammatory
processes. The primary source and target of MIF have been identified as macrophages [106].
MIF is rapidly released in response to inflammatory stimuli such as lipopolysaccharide, TNF-
α, and IFN-γ. MIF can have both paracrine and autocrine effects [106-108]. MIF elevates
adipose tissue inflammation through amplification of migration, recruitment, and activation
of leukocytes at the site of inflammation through upregulation of adhesion molecules such as
ICAM-1 and MCP-1 [109-111]. MIF can utilize its chemotactic properties via CXCR2 and
CXCR4 in macrophages and T cells, respectively [111]. The interaction of MIF with CXCR4 on
the surface of fibroblasts and T cells induced CXCL8 secretion [112]. Interestingly, the alter‐
native MIF receptor CD74, which is traditionally involved in the activation of the mitogen-
activated protein kinases pathway, has recently been demonstrated to also mediate
macrophage chemotactic responses [113, 114]. Although these roles in macrophage recruit‐
ment have been demonstrated, a recent study showed MIF-/-mice did not exhibit significant
changes in ATM content compared to WT mice when fed a HFD [115].
3. Conclusion
Adipose tissue inflammation and macrophage infiltration are well-established features of
obesity. ATMs are separated into at least two groups: M1 and M2. In obesity, more than 90%
of recruited monocytes become M1 macrophages that can secrete proinflammatory cytokines
resulting in adipose tissue inflammation and insulin resistance. Many studies have identified
adipokines that can recruit monocytes into adipose tissue in obesity. Consequently, adipose
tissue-derived chemokines may be promising therapeutic targets for insulin resistance and
metabolic diseases. Although modulation of a single chemokine can affect the chemotaxis of
monocytes when they are studied individually, it is likely that chemokines have overlapping
functions in the more complex in vivo environment. Moreover, the complicated process of
monocyte recruitment and subsequent differentiation into M1 or M2 macrophages in obese
adipose tissue appears to be substantially different in mouse and human obesity, which
emphasizes the need for investigations in humans. Therefore, whether macrophage depletion
stands for an appropriate tool to ameliorate adipose tissue homeostasis and restore insulin
resistance in obesity remains an open question.
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